Compare OXSQ & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | TLSA |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.9M | 164.1M |
| IPO Year | N/A | 2017 |
| Metric | OXSQ | TLSA |
|---|---|---|
| Price | $1.33 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 257.0K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 22.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $1.08 |
| 52 Week High | $2.42 | $2.60 |
| Indicator | OXSQ | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 37.65 | 40.13 |
| Support Level | $1.05 | N/A |
| Resistance Level | $1.95 | $1.54 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 75.00 | 18.83 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.